SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point of intense investor interest as the community awaits crucial Phase 3 data for its gene editing candidate and monitors the regulatory progress of its cardiac pipeline. With short interest levels remaining elevated, investors are actively debating the potential for a volatile move driven by upcoming clinical readouts and the possibility of a squeeze.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors react to a strategic partnership with OpenAI designed to accelerate drug discovery, while the community remains hyper-focused on the evolving competitive landscape against Eli Lilly's weight-loss pills. Conversations are dominated by debates over oral GLP-1 efficacy, long-term prescription velocity, and whether current technical levels signal a bottoming process or a value trap ahead of upcoming earnings.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing significant market interest driven by heavy insider buying from the CEO and growing community speculation regarding potential strategic partnerships with major AI firms. Investors are closely monitoring price action as the stock attempts to reclaim key technical levels, balancing optimism for an ad-tech rebound against ongoing concerns about institutional short positioning and broader software sector volatility.

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing a surge in activity as investors react to the launch of ApeChain and reports of increased on-chain utility. Community sentiment is deeply polarized, with some traders optimistic about a potential breakout driven by fresh volume and whale interest, while others express frustration over historical price volatility and dilution concerns.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors aggressively debate the company's long-term commercial potential, fueled by community speculation surrounding its collaboration with major industry players like Synopsys and Applied Materials. While some discuss a potential breakout driven by its Gate-All-Around transistor technology and perceived short-squeeze setups, skeptical voices emphasize the lack of material revenue and concerns over recurring share offerings.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is seeing intense investor interest following its NASDAQ debut, with the stock drawing significant attention due to its strategic backing from Amazon and its focus on small modular reactor technology. Community discourse is highly active, weighing the potential of the nuclear infrastructure narrative against concerns regarding IPO volatility and the company's long-term path to profitability.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors express significant frustration over the stock's recent underperformance relative to the broader market and a perceived lack of capital deployment by leadership. While some community members view current price levels as a potential value opportunity supported by buybacks, others are vocal in their criticism of the company's massive cash pile and the transition following Warren Buffett's tenure.

Dumb SEND IT

$DSIT is generating significant buzz among community members who are positioning the token as a high-momentum weekend runner, with active discussions focused on breaking through previous market cap milestones. Investors are coordinating social media engagement and highlighting developer-led airdrops to build momentum, while comparisons to other meme coin cycles drive speculation about its growth potential.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is seeing heightened investor attention as market participants track the upcoming Phase 2/3 clinical readout for tovecimig, a key bispecific antibody candidate for biliary tract cancer. The community is actively discussing the stock's binary event setup, weighing the potential for a breakthrough in a high-unmet-need oncology space against the inherent volatility typical of clinical-stage biotechs.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is currently trending as investors weigh the company's decision to maintain financial discipline by exiting the bidding war for Warner Bros. Discovery against the upcoming spinoff of its cable networks into the new Versant Media Group entity. The community remains divided, with some investors praising the stock's low valuation and dividend yield, while others express frustration over persistent broadband subscriber losses and the stock's lack of upward momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Westlake Chemical Partners Announce First Quarter 2026 Conference Call

Westlake Chemical Partners (NYSE: WLKP) will release its first quarter 2026 earnings prior to the market opening on Tuesday, May 5, 2026. The company will host a conference call at 1:00 p.m. Eastern Time (12:00 p.m. Central Time) on the same day to discuss the earnings release. To access the...

Westlake Chemical Partners Appoints Jonathan H. Baksht as Senior Vice President and Chief Financial Officer

Westlake Chemical Partners LP (NYSE: WLKP) (the "Partnership") announced today that Mr. Jonathan H. Baksht will be joining the Partnership as Senior Vice President and Chief Financial Officer and as a director of Westlake Chemical Partners GP LLC, the general partner of the Partnership (the General...

Westlake Chemical Partners LP (NYSE:WLKP) Short Interest Down 20.9% in March

Westlake Chemical Partners LP (NYSE:WLKP - Get Free Report) was the target of a significant drop in short interest during the month of March. As of March 31st, there was short interest totaling...

Westlake Chemical Partners (NYSE:WLKP) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Westlake Chemical Partners from a "buy" rating to a "strong-buy" rating in a report on Saturday...

Wall Street Zen Downgrades Westlake Chemical Partners (NYSE:WLKP) to Buy

Wall Street Zen downgraded Westlake Chemical Partners from a "strong-buy" rating to a "buy" rating in a research note on Saturday...

Westlake Chemical Partners LP Filed Annual Report

Westlake Chemical Partners LP (NYSE: WLKP) (the 'Partnership') announced that it filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 with the Securities and Exchange...

Westlake Chemical Partners (NYSE:WLKP) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Westlake Chemical Partners (NYSE:WLKP - Get Free Report) announced its earnings results on Tuesday. The basic materials company reported $0.41 earnings per share for the quarter, missing the...

Westlake Chemical Partners LP Announces Fourth Quarter and Full Year 2025 Results

Westlake Chemical Partners LP (NYSE: WLKP) (the 'Partnership') today reported net income attributable to the Partnership in the fourth quarter of 2025 of $14.5 million, or $0.41 per limited partner...

WLKP Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Westlake Chemical Partners LP (Symbol: WLKP) crossed below their 200 day moving average of $21.05, changing hands as low as $21.01 per share. Westlake Chemical...

Westlake Chemical Partners (WLKP) Expected to Announce Earnings on Tuesday

Westlake Chemical Partners (NYSE:WLKP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...

Westlake Chemical Partners LP engages in the operation, acquisition and development of ethylene production facilities and related assets. It is also involved in the manufacture and marketing of basic chemicals, polymers, and fabricated building products. The company was founded on March 14, 2014 and is headquartered in Houston, TX.

WLKP
Westlake Chemical Partners LP

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest WLKP News

WLKPWestlake Chemical Partners LP